Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

"These results, combined with the patient satisfaction with the relative ease of providing blood rather than a solidtissue sample, suggest a clinical strategy of pursuing plasma NGS first, then tissue NGS if plasma NGS cannot detect relevant mutations."


Bishal Gyawali, MD, PhD; Howard (Jack) West, MD
Editorial

with tissue genotyping for targetable alterations before first-line NSCLC therapy

Study Overview

Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 can increase the likelihood of finding targetable mutations.

Key findings

were unable to get complete genomic results from tissue biopsy

had targetable alterations detected by Guardant360 and tissue testing (n=82) versus tissue testing alone (n=47)

had a response or stable disease based on RECIST criteria

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

You may also
be interested in...

Patient Brochure

Find treatment options with the ease of a blood draw

View Publication Download material

Clinical cancer research

Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer

View Publication View Publication

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.